Barclays raised the firm’s price target on Insulet (PODD) to $300 from $266 and keeps an Equal Weight rating on the shares. The firm updated the company’s model to reflect management’s commentary and updated 2025 outlook.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD: